AKT is a
signal transduction protein that
plays a central
role in the
tumorigenesis. There are 3 mammalian
isoforms of this
serine/
threonine protein kinase-AKT1, AKT2, and AKT3-showing a broad
tissue distribution. We first discovered 2 novel polymorphisms (AKT2 -9826 C/G and AKT3 -811 A/G), and we confirmed 6 known polymorphisms (AKT2 -9473 C/T, AKT2 -9151 C/T, AKT2 -9025 C/T, AKT2 -8618G/A, AKT3 -675 A/-, and AKT3 -244 C/T) of the AKT2 and AKT3
promoter region in 24
blood samples of Korean
lung cancer patients using direct sequencing. To evaluate the
role of AKT2 and AKT3 polymorphisms in the
risk of Korean
lung cancer,
genotypes of the AKT2 and AKT3 polymorphisms (AKT2 -9826 C/G, AKT2 -9473 C/T, AKT2 -9151 C/T, AKT2 -9025 C/T, AKT2 -8618G/A, and AKT3 -675 A/-) were determined in 360
lung cancer patients and 360 normal controls. Statistical analyses revealed that the
genotypes and
haplotypes in the AKT2 and AKT3
promoter regions were not significantly associated with the
risk of
lung cancer in the Korean
population. These results suggest that polymorphisms of the AKT2 and AKT3
promoter regions do not contribute to the
genetic susceptibility to
lung cancer in the Korean
population.